Larry G Gerdes
CIK 925105 · President & CEO · last filed 2025-04-28
Larry G Gerdes is a President & CEO who has filed 79 SEC Form 4 insider transactions across 2 companies since 2007. The most recent filing shows the insider sold $1.1M of CME on Apr 28, 2025. Across all open-market trades the lifetime net is −$50.9M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $11.7M across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
TRCR price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
SUITE 1325
ATLANTA, GA 30326
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| CME | Director | 39,651 | $293.87 | $11.65M | -$318.6K | 25 | 2025-04-28 |
| TRANSCEND SERVICES INC (TRCR) Delisted | President & CEO | 0 | — | — | -$50.62M | 42 | 2012-04-27 |
Recent Filings
79 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2025-04-28 | CME | Sell (S) | −4,000 | -$1.06M | EDGAR |
| 2025-04-25 | CME | Notice (144) | −2,000 | -$532.2K | EDGAR |
| 2025-04-24 | CME | Notice (144) | −2,000 | -$528.2K | EDGAR |
| 2024-06-26 | CME | Grant (A) | +1,237 | $240.1K | EDGAR |
| 2023-06-28 | CME | Grant (A) | +1,342 | $240.1K | EDGAR |
| 2022-06-29 | CME | Grant (A) | +1,146 | $240.0K | EDGAR |
| 2022-01-26 | CME | Grant (A) | +75 | $16.6K | EDGAR |
| 2021-06-29 | CME | Grant (A) | +917 | $200.0K | EDGAR |
| 2020-06-29 | CME | Grant (A) | +1,186 | $0 | EDGAR |
| 2019-06-27 | CME | Grant (A) | +1,009 | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.